Bellicum Pharmaceuticals, Inc.
Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel
Results show high rates of Relapse Free Survival and Overall Survival in pediatric patients with acute leukemias with median follow-up of 17 months
December 2, 2018